Gemma Tell-Martí

Gemma Tell-Martí

Auto-generated profile, based on publicly available information

Gemma Tell-Martí

Center for Biomedical Network Research on Rare Diseases (CIBERER) Carlos III Health Institute Barcelona Spain

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
VSVanessa Martins da Silva
Vanessa Martins da Silva
EMEstefania Martinez-Barrios
Estefania Martinez-Barrios
GTGemma Tell-Martí
Gemma Tell-Martí
MDMarc Dabad
Marc Dabad
CCCristina Carrera
Cristina Carrera
JMJosep Malvehy
Josep Malvehy

16 December 2013 in Oncotarget
Verified
Journal Article
Open access
PDF file
JPJoan Anton Puig-Butille
Joan Anton Puig-Butille
Maria José EscámezMaria José Escámez
Maria José Escámez
FGFrancisco García García
Francisco García García
GTGemma Tell-Marti
Gemma Tell-Marti
ÀFÀngels Fabra
Àngels Fabra
SPSusana Puig
Susana Puig
Germline mutations in CDKN2A and/or red hair color variants in MC1R genes are associated with an increased susceptibility to develop cutaneous melanoma or non melanoma skin cancer.

1 June 2017 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
JPJoan Anton Puig-Butille
Joan Anton Puig-Butille
AVAntònia Vinyals
Antònia Vinyals
JFJosep R. Ferreres
Josep R. Ferreres
PAPaula Aguilera
Paula Aguilera
ECEduard Cabré
Eduard Cabré
ÀFÀngels Fabra
Àngels Fabra

9 April 2015 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
DSD. Shitara
D. Shitara
GTG. Tell-Martí
G. Tell-Martí
CBCelia Badenas
Celia Badenas
MEM.M.S.S. Enokihara
M.M.S.S. Enokihara
LAL. Alós
L. Alós
EBE. Bagatin
E. Bagatin
Background The origin of melanoma has always been a debated subject, as well as the role of adjacent melanocytic naevi. Epidemiological and histopathological studies point to melanomas arising either de novo or from a naevus. Objectives To evaluate the presence of mutations in genes from well‐known melanomagenesis pathways in a large series of naevus‐associated melanomas. Materials and methods Sixty‐one melanomas found in association with a pre‐existing naevus were microdissected, after careful selection of cell subpopulations, and submitted to Sanger sequencing of the BRAF, NRAS, c‐KIT, PPP6C, STK19 and RAC1 genes. Each gene was evaluated twice in all samples by sequencing or by sequencing and another confirmation method, allele‐specific fluorescent polymerase chain reaction (PCR) and capillary electrophoresis detection or by SNaPshot analysis. Only mutations confirmed via two different molecular methods or twice by sequencing were considered positive. Results The majority of cases presented concordance of mutational status between melanoma and the associated naevus for all six genes (40 of 60; 66·7%). Nine cases presented concomitant BRAF and NRAS mutations, including one case in which both the melanoma and the adjacent naevus harboured V600E and Q61K double mutations. In two cases, both melanoma and associated naevus located on acral sites were BRAF mutated, including an acral lentiginous melanoma. Conclusions To our knowledge this is the largest naevus‐associated melanoma series evaluated molecularly. The majority of melanomas and adjacent naevi in our sample share the same mutational profile, corroborating the theory that the adjacent naevus and melanoma are clonally related and that the melanoma originated within a naevus.

29 January 2015 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
GTGemma Tell‐Marti
Gemma Tell‐Marti
JPJoan Anton Puig‐Butille
Joan Anton Puig‐Butille
MPMiriam Potrony
Miriam Potrony
CBCelia Badenas
Celia Badenas
MMMontserrat Milà
Montserrat Milà
SPSusana Puig
Susana Puig

1 April 2016 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
MPMiriam Potrony
Miriam Potrony
JPJoan Anton Puig-Butille
Joan Anton Puig-Butille
PAPaula Aguilera
Paula Aguilera
CBCelia Badenas
Celia Badenas
GTGemma Tell-Marti
Gemma Tell-Marti
SPSusana Puig
Susana Puig
Approximately 8% to 12% of melanoma cases occur in a familial context.1 The main high-penetrance gene implicated in melanoma susceptibility is CDKN2A (OMIM code: 600160; GenBank accession number: NM_000077.4 [p16INK4A] and NM_058195.3 [p14ARF]). The gene encodes 2 tumor suppressor proteins: p16INK4A, which promotes cell-cycle arrest and plays a role in senescence, and p14ARF, which acts through p53-regulating apoptosis.2,3 Germline CDKN2A mutations are found in 20% to 40% of melanoma-prone families4 and in 8% to 16% of patients with multiple primary melanomas without other cases in the family.5 Patients with melanoma carrying CDKN2A mutations have a younger age of onset and a higher number of primary melanomas, and the presence of CDKN2A mutations is associated with dysplastic nevi.4-7